Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-p53 TCR-Gene Engineered Lymphocytes and DC Vaccine in Metastatic Cancer
NCT00704938Phase 2Terminated
- Sponsor
- National Institutes of Health
- Start
- Jun 2008
- Primary completion
- Aug 2009
- Modality
- Whole Cell Cancer Vaccines, TCR-Engineered T Cells, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous p53-specific T cells and Ad.p53-DC vaccine in metastatic cancer, kidney cancer, melanoma and 1 more (2 arms), sponsored by National Institutes of Health. Primary endpoint: Clinical Response (Complete Response + Partial Response) at 5 months. Started Jun 2008; status: terminated.
02
Drugs
autologous p53-specific T cellsAd.p53-DC vaccine
03
Conditions
metastatic cancerkidney cancermelanomasolid tumor
Beyond the preview
Go deeper on NCT00704938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704938.